In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody

Oncology Reports

Volumn 26, Issue 4, 2011, Pages 949-955

  Watanabe, Yasuhiro ^a   Asano, Ryutaro ^b   Arai, Kyoko ^b   Shimomura, Ippei ^b   Ogata, Hiromi ^b   Kawaguchi, Hiroko ^b   Hayashi, Hiroki ^a   Ohtsuka, Hideo ^a   Yoshida, Hiroshi ^a   Katayose, Yu ^a   Egawa, Shinichi ^a   Nakanishi, Takeshi ^b   Umetsu, Mitsuo ^b   Yasui, Hiroshi ^c   Ishida, Tadao ^c   Imai, Kohzoh ^c   Kudo, Toshio ^b   Unno, Michiaki ^a   Kumagai, Izumi ^b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bispecific diabody; Cancer immunotherapy; Effective recombinant formats; EGFR; IgG like bispecific antibody

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR DIABODY; EPIDERMAL GROWTH FACTOR RECEPTOR SINGLE CHAIN DIABODY; EPIDERMAL GROWTH FACTOR RECEPTOR SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; MICE; MICE, SCID; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960789752     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1382     Document Type: Article

References (39)

1. Fischer-Colbrie J, Witt A, Heinzl H, et al: EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 17: 613-619, 1997. (Pubitemid 27105536)
2. Nonomura A, Ohta G, Nakanuma Y, et al: Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method. Liver 8: 157-166, 1988.
3. Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
4. Tosi E, Valota O, Negri DR, et al: Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab′)2 fragment against high- and low-EGFR-expressing carcinomas in nude mice. Int J Cancer 62: 643-650, 1995.
5. Jung G, Brandl M, Eisner W, et al: Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy. Int J Cancer 91: 225-230, 2001. (Pubitemid 32041744)
6. Pfosser A, Brandl M, Salih H, Grosse-Hovest L and Jung G: Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study. Int J Cancer 80: 612-616, 1999. (Pubitemid 29047529)
7. Reusch U, Sundaram M, Davol PA, et al: Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 12: 183-190, 2006. (Pubitemid 43166193)
8. Cao Y and Lam L: Bispecific antibody conjugates in therapeutics. Adv Drug Deliv Rev 55: 171-197, 2003. (Pubitemid 36135915)
9. Kufer P, Lutterbuse R and Baeuerle PA: A revival of bispecific antibodies. Trends Biotechnol 22: 238-244, 2004. (Pubitemid 38515741)
10. Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M and Little M: A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. Blood 94: 2562-2568, 1999. (Pubitemid 29477283)
11. Alt M, Muller R and Kontermann RE: Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett 454: 90-94, 1999. (Pubitemid 29296932)
12. Schlereth B, Fichtner I, Lorenczewski G, et al: Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 65: 2882-2889, 2005. (Pubitemid 40490092)
13. Wu AM, Chen W, Raubitschek A, et al: Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 2: 21-36, 1996. (Pubitemid 26096269)
14. Cochlovius B, Kipriyanov SM, Stassar MJ, et al: Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells. J Immunol 165: 888-895, 2000. (Pubitemid 30484756)
15. Asano R, Sone Y, Makabe K, et al: Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 12: 4036-4042, 2006. (Pubitemid 44078091)
16. Asano R, Ikoma K, Sone Y, et al: Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody. J Biol Chem 285: 20844-20849, 2010.
17. Park SS, Ryu CJ, Kang YJ, Kashmiri SV and Hong HJ: Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens. Mol Immunol 37: 1123-1130, 2000. (Pubitemid 32635164)
18. Shen J, Vil MD, Jimenez X, et al: Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. J Immunol Methods 318: 65-74, 2007. (Pubitemid 46026806)
19. Lu D, Zhang H, Ludwig D, et al: Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 279: 2856-2865, 2004. (Pubitemid 38114277)
20. Carter P: Bispecific human IgG by design. J Immunol Methods 248: 7-15, 2001.
21. Lu D, Jimenez X, Zhang H, et al: Di-diabody: a novel tetravalent bispecific antibody molecule by design. J Immunol Methods 279: 219-232, 2003. (Pubitemid 37297506)
22. Marvin JS and Zhu Z: Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 26: 649-658, 2005. (Pubitemid 40806552)
23. Asano R, Watanabe Y, Kawaguchi H, et al: Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem 282: 27659-27665, 2007. (Pubitemid 47529493)
24. Asano R, Kawaguchi H, Watanabe Y, et al: Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells. J Immunother 31: 752-761, 2008.
25. Asano R, Sone Y, Ikoma K, et al: Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528. Protein Engin Des Sel 21: 597-603, 2008.
26. Yamada N, Chung YS, Arimoto Y, Sawada T, Seki S and Sowa M: Establishment of a new human extrahepatic bile duct carcinoma cell line (OCUCh-LM1) and experimental liver metastatic model. Br J Cancer 71: 543-548, 1995.
27. Saijyo S, Kudo T, Suzuki M, et al: Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med 177: 61-71, 1995.
28. Asano R, Ikoma K, Kawaguchi H, et al: Application of the Fc fusion format to generate tag-free bi-specific diabodies. FEBS J 277: 477-487, 2009.
29. Katayose Y, Kudo T, Suzuki M, et al: MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Cancer Res 56: 4205-4212, 1996. (Pubitemid 26305017)
30. Asano R, Ikoma K, Shimomura I, et al: Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody. J Biol Chem 286: 1812-1818, 2011.
31. Merchant AM, Zhu Z, Yuan JQ, et al: An efficient route to human bispecific IgG. Nat Biotechnol 16: 677-681, 1998. (Pubitemid 28334328)
32. Ridgway JB, Presta LG and Carter P: 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9: 617-621, 1996. (Pubitemid 26241639)
33. Xie Z, Guo N, Yu M, Hu M and Shen B: A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods 296: 95-101, 2005. (Pubitemid 40174743)
34. Clynes RA, Towers TL, Presta LG and Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446, 2000. (Pubitemid 30208162)
35. Dwek RA: Glycobiology: more functions for oligosaccharides. Science 269: 1234-1235, 1995.
36. Jefferis R: Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8: 226-234, 2009.
37. Kim WD, Tokunaga M, Ozaki H, et al: Glycosylation pattern of humanized IgG-like bispecific antibody produced by recombinant CHO cells. Appl Microbiol Biotechnol 85: 535-542, 2010.
38. Fan Z, Lu Y, Wu X and Mendelsohn J: Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269: 27595-27602, 1994. (Pubitemid 24346592)
39. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H and Fujii H: Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 120: 781-787, 2007. (Pubitemid 46175397)